Grant will help UK Cooperative Extension Service expand opioid prevention and recovery efforts

The University of Kentucky Cooperative Extension Service has received a two-year grant to further its statewide efforts in opioid prevention and recovery, Katie Pratt reports for UK.

The more than $1 million grant from the Substance Abuse and Mental Health Services Administration will allow the program to expand its efforts to Southern and Western Kentucky.

As part of the grant, the program will offer an Addiction 101 course to discuss the science behind addiction, including genetic and hereditary risk factors for developing addiction disorder. Pratt reports that the course will be geared toward health-care workers, extension agents and community leaders and will be led by Alex Elswick, UK extension specialist for substance use prevention and recovery.

“We want to remove the stigmas associated with addiction, so health care workers and community members feel more comfortable and equipped to help those struggling with opioid use addiction and recovery,” Elswick told Pratt.

Other grant programs will include administering an evidence-based substance abuse program for middle-school students, called Botvin LifeSkills Training and an art program to provide individuals with a therapeutic outlet to express their feelings related to substance use and addiction, she writes.

In addition, Pratt reports that the extension program will be expanding its financial-education curriculum that specifically addresses money issues faced by those in recovery. The program, called "Recovering your Finances," was developed by Elswick and Kelly May, a UK senior extension associate. It is  being piloted in Mercer County and will be offered in Boyd, Bourbon, Knox and Leslie counties through a separate grant from the U.S. Department of Agriculture.

Pratt notes that many of these programs grant will build on the extension service’s existing programs to reduce opioid use and help recovery efforts, including efforts to teach gardening, nutrition and life skills to those in recovery, and support programs for families with a loved one with a substance-use disorder. Extension will also continue to offer support to local community health coalitions that address substance-use prevention and recovery, Pratt reports.

“The Kentucky Cooperative Extension Service is currently recognized as a leader among the land-grant university system for outreach efforts targeting substance use prevention and recovery,” Jennifer Hunter, assistant director for family and consumer sciences extension and one of the co-leaders on the grant, told Pratt.  “We are excited to be able to continue to expand our educational efforts and enhance the level of resources available at the community level.”

Read More

Harvard Health Ad Watch: A fibromyalgia treatment (“But you look so good!”)

It’s something I’ve heard countless times from patients with fibromyalgia. They’re telling a friend or family member about their condition and the response is, “But you don’t look sick” or “But you look so well.” Sometimes, the reaction is more of an eye roll or some other response that reflects skepticism that the problem is even “real.”

Those are issues addressed head-on in a TV ad for Lyrica (pregabalin), a treatment for fibromyalgia. “To most people, I look like most people,” a woman says. “But on the inside I feel chronic, widespread pain.” After clarifying that the pain is real, this direct-to-consumer drug advertisement moves on to say one of the current theories about the origin of pain in fibromyalgia is that it’s “thought to be caused by overactive nerves.”

The mood of the ad is somber at first. Sad music serves as backdrop to a woman who is clearly suffering as a man — perhaps her husband? — plays in the park with two adorable kids. That all changes when she talks about taking Lyrica. Then the music soars and the voiceover tells us that “Lyrica is believed to calm these nerves.” The now-smiling woman looks into the camera and pronounces, “I’m glad my doctor prescribed Lyrica.” The scene brightens and she’s smiling as she goes about setting up for a neighborhood block party. The voiceover informs us that, “For some, Lyrica delivers effective relief for fibromyalgia pain and improves function.”

Then comes the litany of side effects that might accompany treatment. More on those shortly.

The good

The ad gets a number of things right, including:

• the fact that the condition may be “invisible” to others
• the notion that the cause of fibromyalgia is unknown, but experts believe it may be due to “overactive nerves”
• the character in the ad who has fibromyalgia is a woman — in fact, the condition is up to six times more common in women than men
• mentioning the risks (and not just benefits) of a medication is important. The most common, and many rare, potential side effects are described. Keep in mind, though, that including a description of side effects or referring consumers to more information is required by the FDA, as I noted in my initial blog on direct-to-consumer ads describing pros, cons, and words to consider very carefully).

What’s missing

Some important information is missing from this ad, including:

• The limited effectiveness of the drug. Note the language in the ad: Lyrica works well “for some.” You might wonder just how many “some” is! A recent analysis of past studies found that only about 10% of treated study subjects reported excellent results, and only about 40% reported very good or excellent results. Lyrica was only modestly better than a placebo pill. Another analysis found that among prior studies, only 20% to 25% of study subjects experienced “at least 50% pain intensity reduction” within two to three months of treatment.
• The ad only mentions one treatment option: medication. But that’s not the only option. In fact, nondrug options, such as regular exercise and improved sleep, are considered vital for the successful treatment of fibromyalgia.
• No comparison to other medications. A number of other medications are approved and prescribed for fibromyalgia, yet there’s no mention of how Lyrica measures up to these other medications prescribed. According to a recent review, Lyrica seems to be no better (or worse) than other approved medications, including milnacipran (Savella) and duloxetine (Cymbalta).
• As with nearly all drug ads, the price of the drug is not mentioned. In November, the price of Lyrica was about $12 per 75-mg capsule, according to Drugs.com. The recommended starting dose is 75 mg twice daily, which adds up to around $24/day or more than $760/month. Often, higher doses are needed, which pushes the price even higher. Of course, medication costs are a moving target, because health insurance coverage, copayments, deductibles, drug company coupons, and other factors may affect the price you pay.

The risks of treatment

The list of side effects in this commercial is so long that many (or perhaps most) viewers will tune out. While common side effects include dizziness, sleepiness, weight gain, or swelling of the extremities, “severe allergic reactions” and “suicidal thoughts or actions” are the first ones mentioned. These risks are listed against a visually interesting and wonderfully distracting backdrop — in this ad, it’s giant bubbles and puppies. Yes, bubbles and puppies! Maybe providing a distraction from the list of things that could go wrong if you take Lyrica is not a coincidence. In fact, most drug ads do this.

The bottom line

Ads for drugs are not meant to be thorough or balanced. Their intent is to increase sales of their drug. Drug makers often talk about the importance of these ads to educate the public about treatment options. But the obvious (and understandable) bias toward the drug being advertised — Lyrica, in this case — makes the quality of the education suspect. That’s why I’m opposed to direct advertising to consumers for medications and medical procedures, and that’s probably a reason most countries don’t allow it.

Yes, fibromyalgia is a real and troublesome condition that’s invisible to others. But medication treatment, such as Lyrica, is only one part of standard treatment. And it’s not always effective. Want more complete and balanced information about fibromyalgia? Talk to your doctor or consult unbiased sources that aren’t trying to sell you anything. A pharmaceutical advertisement may not be your best bet.

The post Harvard Health Ad Watch: A fibromyalgia treatment (“But you look so good!”) appeared first on Harvard Health Blog.

Read More

Medical News Today: What to know about fissured tongue

Fissured tongue causes a person to develop one or multiple grooves on their tongue. It is not usually a serious condition but can lead to some mild complications. Read this article to learn more about the causes and treatment.

Read More

Medical News Today: Pink eye in toddlers: Everything you need to know

Pink eye is a common eye problem in toddlers. Infections, eye irritation, and allergies can all cause pink eye. Here we look at symptoms to watch out for, treatment options, and prevention.

Read More

Medical News Today: Blood pressure chart: Ranges and guide

A person’s blood pressure is one indication of their overall heart health. Learn about healthy blood pressure ranges and when to see a doctor in this article.

Read More

Medical News Today: What are the effects of emotional abuse?

Emotional abuse is a serious form of abuse that can have both short- and long-term effects. Learn about how to spot the signs of emotional abuse and how to seek or provide help here.

Read More

Medical News Today: The brain finds a way to adapt, even when we remove half

Some people undergo surgery to remove half of the brain to stop seizures. Evidence suggests that this does not significantly alter brain function.

Read More